Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...

A novel blood-based test for early detection of colorectal cancer in average-risk adults met the primary endpoints of ...

The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

If the drug is approved by the US Food and Drug Administration for the treatment of acute pain in January as expected, the ...

Genentech, a member of Roche (RHHBY), announced topline results from the overall survival analysis of the Phase III INAVO120 study ...

The effective use of ADA in bioprocessing, though, requires a multidisciplinary team, from a program lead and subject-matter ...

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 ...

Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 11.26%, which has investors questioning if this is right time ...

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

The company, co-founded by Nobel Laureate Craig Mello, aims to push molecules for Huntington’s and a form of epilepsy into ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...